TScan Therapeutics (TCRX) Assets (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Assets data on file, last reported at $202.0 million in Q1 2026.

• On a quarterly basis, Assets fell 39.29% year-over-year to $202.0 million in Q1 2026; TTM through Mar 2026 was $202.0 million, a 39.29% decrease from a year earlier, with the FY2025 full-year figure at $228.8 million, down 38.35% from the prior year.
• Assets for Q1 2026 stood at $202.0 million, down from $228.8 million in the prior quarter.
• Over the last five years, Assets for TCRX reached as high as $374.9 million in Q2 2024 and fell as low as $152.4 million in Q2 2022.
• Historically, Assets has averaged $258.7 million across 5 years, with a median of $262.2 million in 2025.
• Across the five-year window, Assets soared 107.93% in 2023 and tumbled 39.29% in 2026, its largest moves.
• Year by year, Assets stood at $199.1 million in 2022, then surged by 36.7% to $272.1 million in 2023, then jumped by 36.37% to $371.1 million in 2024, then plunged by 38.35% to $228.8 million in 2025, then retreated by 11.71% to $202.0 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $202.0 million in Q1 2026, $228.8 million in Q4 2025, and $262.2 million in Q3 2025.